Jiangxi Bio Gains Regulatory Green Light for Veterinary Tetanus Antitoxin, Expanding Animal Health Pipeline

Bulletin Express

11 hours ago

Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that its wholly owned subsidiary, Chifeng Bo-en Pharmaceutical Co., Ltd., has secured the Approval Certificate of Veterinary Drug Product for its veterinary tetanus antitoxin.

The newly approved product is designed to prevent and treat tetanus in animals by providing passive immune protection through toxin neutralisation. Management emphasises that the certification adds a differentiated biologic to the Group’s existing portfolio and establishes a platform for deeper penetration into the animal-health segment.

According to the Board, the licence is expected to enhance Jiangxi Bio’s overall competitiveness and support its long-term development strategy. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1106495850"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106495850\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106495850?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 06:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106495850","market":"us","top_or_hot":-1,"title":"Jiangxi Bio Gains Regulatory Green Light for Veterinary Tetanus Antitoxin, Expanding Animal Health Pipeline","media":"Bulletin Express","content":"<p>Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that its wholly owned subsidiary, Chifeng Bo-en Pharmaceutical Co., Ltd., has secured the Approval Certificate of Veterinary Drug Product for its veterinary tetanus antitoxin.</p>\n<p>The newly approved product is designed to prevent and treat tetanus in animals by providing passive immune protection through toxin neutralisation. Management emphasises that the certification adds a differentiated biologic to the Group’s existing portfolio and establishes a platform for deeper penetration into the animal-health segment.</p>\n<p>According to the Board, the licence is expected to enhance Jiangxi Bio’s overall competitiveness and support its long-term development strategy. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangxi Bio Gains Regulatory Green Light for Veterinary Tetanus Antitoxin, Expanding Animal Health Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangxi Bio Gains Regulatory Green Light for Veterinary Tetanus Antitoxin, Expanding Animal Health Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-03 06:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that its wholly owned subsidiary, Chifeng Bo-en Pharmaceutical Co., Ltd., has secured the Approval Certificate of Veterinary Drug Product for its veterinary tetanus antitoxin.</p>\n<p>The newly approved product is designed to prevent and treat tetanus in animals by providing passive immune protection through toxin neutralisation. Management emphasises that the certification adds a differentiated biologic to the Group’s existing portfolio and establishes a platform for deeper penetration into the animal-health segment.</p>\n<p>According to the Board, the licence is expected to enhance Jiangxi Bio’s overall competitiveness and support its long-term development strategy. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06915","symbol_name":"江西生物","start_time":0,"source_url":"","article_id":"1106495850","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106495850","pubTimestamp":1783032232,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that its wholly owned subsidiary, Chifeng Bo-en Pharmaceutical Co., Ltd., has secured the Approval Certificate of Veterinary Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06915":"江西生物"},"translate_title":"江西生物兽用破伤风抗毒素获监管绿灯拓展动物保健管线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06915":1},"content_text":"Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that its wholly owned subsidiary, Chifeng Bo-en Pharmaceutical Co., Ltd., has secured the Approval Certificate of Veterinary Drug Product for its veterinary tetanus antitoxin.\nThe newly approved product is designed to prevent and treat tetanus in animals by providing passive immune protection through toxin neutralisation. Management emphasises that the certification adds a differentiated biologic to the Group’s existing portfolio and establishes a platform for deeper penetration into the animal-health segment.\nAccording to the Board, the licence is expected to enhance Jiangxi Bio’s overall competitiveness and support its long-term development strategy. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}